<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323492</url>
  </required_header>
  <id_info>
    <org_study_id>GS-FR-164-0109</org_study_id>
    <nct_id>NCT00323492</nct_id>
  </id_info>
  <brief_title>TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada</brief_title>
  <acronym>TOTEM</acronym>
  <official_title>Open-label Randomized Multicenter Trial to Evaluate the Impact on the Lipid Profile of the Substitution of the NRTIs of a HAART Regimen by a Once Daily Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Maintained Treatment in HIV Infected Controlled Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looked at lipid changes in human immunodeficiency virus type 1 (HIV-1) infected
      patients when the nucleoside reverse transcriptase inhibitors (NRTIs) in their existing
      highly active antiretroviral therapy (HAART) regimen were switched to TruvadaÂ® (a fixed dose
      combination tablet of emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg [FTC/TDF]).
      Subjects continued their nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease
      inhibitor (PI) at the same dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase IV, multicenter (in France), open label study. The study was conducted in
      two phases: a comparative randomized phase, which served the primary objective of the study,
      and a follow-up phase.

      Study Phase 1, Day -14 to Week 12: patients were randomized on a 1:1 basis to one of two
      groups:

        -  A. Truvada (substitution of their current NRTIs by Truvada [FTC/TDF] with continuation
           of their current NNRTI or PI at the same dose)

        -  B. Maintain Baseline Regimen (continuation of previous HAART regimen, i.e., maintained
           baseline regimen).

      This phase of the study served the primary objective of the study.

      Study Phase 2, roll-over follow-up, Week 12 to Week 48: Patients in the Truvada group
      continued with Truvada + an NNRTI or PI. Patients in the control group could switch their
      NRTIs to Truvada in this phase of the study (Delayed Truvada group).

      Patients were assessed for efficacy and safety during both phases of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in Fasting Triglycerides</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in Fasting Low-density Lipoprotein Cholesterol (LDL-CHO)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Fasting High-density Lipoprotein Cholesterol (HDL-CHO)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Fasting Total Cholesterol (T-CHO)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Fasting T-CHO/HDL-CHO</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Fasting HDL-CHO/LDL-CHO</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Fasting Ultra-sensitive C-reactive Protein (Us-CRP)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Fasting Plasma Triglycerides &gt; 10 g/L (&gt; 11.29 mmol/L) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Cluster Determinant 4 (CD4) Cell Count</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in CD4 Cell Count</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Control (Plasma HIV-1 Ribonucleic Acid [RNA] &lt; 400 Copies/mL) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1 RNA Greater Than or Equal to 400 Copies/mL at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1 RNA &lt; 400 Copies/mL at Week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Truvada</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Truvada once daily with continuation of the current NNRTI or PI at randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintain Baseline Regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintain baseline regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Truvada</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Truvada once daily with NNRTI or PI (participants from the comparator group who switched to Truvada during Study Phase 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>All Truvada</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Truvada once daily with NNRTI or PI (all participants who received Truvada during the study, i.e., participants in the Truvada and Delayed Truvada groups)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>Truvada + NNRTI or PI.</description>
    <arm_group_label>Truvada</arm_group_label>
    <arm_group_label>Delayed Truvada</arm_group_label>
    <arm_group_label>All Truvada</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Current HAART regimen</intervention_name>
    <description>Maintain baseline regimen</description>
    <arm_group_label>Maintain Baseline Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients displaying abnormal fasted triglycerides (&gt; 2 g/L [2.26 mmol/L] and less than
             or equal to 10 g/L [11.29 mmol/L]) and/or fasted low density lipoprotein cholesterol
             (LDL-CHO; &gt; 1.6 g/L [4.15 mmol/L])

          -  Patients on stable HAART with 2 NRTIs + 1 NNRTI or 1 PI for at least 3 months prior to
             screening, and with plasma viral load &lt; 400 copies/mL for at least 6 months prior to
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camille Aubron-Olivier</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gilead Sciences</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2006</study_first_submitted>
  <study_first_submitted_qc>May 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2006</study_first_posted>
  <results_first_submitted>March 20, 2009</results_first_submitted>
  <results_first_submitted_qc>November 20, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2009</results_first_posted>
  <last_update_submitted>January 13, 2010</last_update_submitted>
  <last_update_submitted_qc>January 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Camille Aubron-Olivier</name_title>
    <organization>Gilead Sciences</organization>
  </responsible_party>
  <keyword>HIV 1 Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Truvada</title>
          <description>Truvada + nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI).</description>
        </group>
        <group group_id="P2">
          <title>Maintain Baseline Regimen</title>
          <description>Maintain baseline regimen.</description>
        </group>
        <group group_id="P3">
          <title>Delayed Truvada</title>
          <description>Truvada + NNRTI or PI (participants from the control group who switched NRTIs to Truvada during Study Phase 2).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study Phase 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="0">Not applicable to Phase 1.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-Treat (ITT) Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="46">One subject was excluded from ITT analysis set due to protocol violation.</participants>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Phase 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44">1/45 subjects completed Phase 1 but did not start Phase 2. Week 48 ITT N=46</participants>
                <participants group_id="P2" count="18">2/45 subjects completed Phase 1 but did not start Phase 2. Week 48 ITT N=20 (no switch to Truvada)</participants>
                <participants group_id="P3" count="25">N=25 switched to Truvada in Phase 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study schedule</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Truvada</title>
          <description>Truvada + NNRTI or PI.</description>
        </group>
        <group group_id="B2">
          <title>Maintain Baseline Regimen</title>
          <description>Maintain baseline regimen.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="10.7" lower_limit="42.0" upper_limit="58.0"/>
                    <measurement group_id="B2" value="43.0" spread="7.7" lower_limit="39.0" upper_limit="50.0"/>
                    <measurement group_id="B3" value="47.0" spread="9.8" lower_limit="41.0" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with plasma HIV-1 RNA &lt; 400 copies/mL</title>
          <description>At screening</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cluster determinant 4 (CD4) cell count</title>
          <description>At screening</description>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="467" lower_limit="314" upper_limit="698"/>
                    <measurement group_id="B2" value="559" lower_limit="337" upper_limit="714"/>
                    <measurement group_id="B3" value="528" lower_limit="318" upper_limit="709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low density lipoprotein cholesterol (LDL-CHO)</title>
          <description>Centralized laboratory assessment</description>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" lower_limit="3.2" upper_limit="4.7"/>
                    <measurement group_id="B2" value="4.0" lower_limit="3.6" upper_limit="4.8"/>
                    <measurement group_id="B3" value="4.0" lower_limit="3.4" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <description>Centralized laboratory assessment</description>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" lower_limit="1.9" upper_limit="4.0"/>
                    <measurement group_id="B2" value="2.7" lower_limit="1.9" upper_limit="3.6"/>
                    <measurement group_id="B3" value="2.4" lower_limit="1.9" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in Fasting Triglycerides</title>
        <description>Centralized laboratory assessment. Change = Week 12 value minus baseline value.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITT. Last post-baseline observation carried forward (LOCF) method was used for the analysis if the Week 12 value was missing. A missing datum were replaced by the last post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Fasting Triglycerides</title>
          <description>Centralized laboratory assessment. Change = Week 12 value minus baseline value.</description>
          <population>ITT. Last post-baseline observation carried forward (LOCF) method was used for the analysis if the Week 12 value was missing. A missing datum were replaced by the last post-baseline value.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-1.2" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.8" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were applied.</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.86</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
            <estimate_desc>Difference is for Truvada minus Maintain Baseline Regimen. The non-parametric estimate of the difference between groups (Hodges-Lehmann) and its 95% confidence intervals (Moses) are provided.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in Fasting Low-density Lipoprotein Cholesterol (LDL-CHO)</title>
        <description>Centralized laboratory assessment. Change = Week 12 value minus baseline value.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITT. LOCF method was used for the analysis if the Week 12 value was missing. A missing datum were replaced by the last post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Fasting Low-density Lipoprotein Cholesterol (LDL-CHO)</title>
          <description>Centralized laboratory assessment. Change = Week 12 value minus baseline value.</description>
          <population>ITT. LOCF method was used for the analysis if the Week 12 value was missing. A missing datum were replaced by the last post-baseline value.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-1.0" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.5" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum text</method>
            <method_desc>No adjustments were made.</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
            <estimate_desc>Difference is for Truvada minus Maintain Baseline Regimen. The non-parametric estimate of the difference between groups (Hodges-Lehmann) and its 95% confidence intervals (Moses) are provided.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Fasting High-density Lipoprotein Cholesterol (HDL-CHO)</title>
        <description>Centralized laboratory assessment. Change = Week 12 value minus baseline value.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITT. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Fasting High-density Lipoprotein Cholesterol (HDL-CHO)</title>
          <description>Centralized laboratory assessment. Change = Week 12 value minus baseline value.</description>
          <population>ITT. Missing values were excluded.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.2" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
            <estimate_desc>Difference is for Truvada minus Maintain Baseline Regimen. The non-parametric estimate of the difference between groups (Hodges-Lehmann) and its 95% confidence intervals (Moses) are provided.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Fasting Total Cholesterol (T-CHO)</title>
        <description>Centralized laboratory assessment. Change = Week 12 value minus baseline value.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITT. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Fasting Total Cholesterol (T-CHO)</title>
          <description>Centralized laboratory assessment. Change = Week 12 value minus baseline value.</description>
          <population>ITT. Missing values were excluded.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-1.3" upper_limit="-0.1"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.7" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wicoxon Rank Sum test</method>
            <method_desc>no adjustments were made.</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
            <estimate_desc>Difference is for Truvada minus Maintain Baseline Regimen. The non-parametric estimate of the difference between groups (Hodges-Lehmann) and its 95% confidence intervals (Moses) are provided.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Fasting T-CHO/HDL-CHO</title>
        <description>Centralized laboratory assessment. Change = Week 12 value minus baseline value.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITT. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Fasting T-CHO/HDL-CHO</title>
          <description>Centralized laboratory assessment. Change = Week 12 value minus baseline value.</description>
          <population>ITT. Missing values were excluded.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-0.7" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.8" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
            <estimate_desc>Difference is for Truvada minus Maintain Baseline Regimen. The non-parametric estimate of the difference between groups (Hodges-Lehmann) and its 95% confidence intervals (Moses) are provided.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Fasting HDL-CHO/LDL-CHO</title>
        <description>Centralized laboratory assessment. Change = Week 12 value minus baseline value.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITT. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Fasting HDL-CHO/LDL-CHO</title>
          <description>Centralized laboratory assessment. Change = Week 12 value minus baseline value.</description>
          <population>ITT. Missing values were excluded.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
            <estimate_desc>Difference is for Truvada minus Maintain Baseline Regimen. The non-parametric estimate of the difference between groups (Hodges-Lehmann) and its 95% confidence intervals (Moses) are provided.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Fasting Ultra-sensitive C-reactive Protein (Us-CRP)</title>
        <description>Local laboratory assessment. Change = Week 12 value minus baseline value.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITT. Missing values were excluded. Assessment of us-CRP was added to the study schedule via protocol amendment part way through the study. This resulted in small numbers of subjects having data available for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Fasting Ultra-sensitive C-reactive Protein (Us-CRP)</title>
          <description>Local laboratory assessment. Change = Week 12 value minus baseline value.</description>
          <population>ITT. Missing values were excluded. Assessment of us-CRP was added to the study schedule via protocol amendment part way through the study. This resulted in small numbers of subjects having data available for this analysis.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-0.5" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-3.2" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Fasting Plasma Triglycerides &gt; 10 g/L (&gt; 11.29 mmol/L) at Week 12</title>
        <description>Centralized laboratory assessment</description>
        <time_frame>12 weeks</time_frame>
        <population>ITT. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Fasting Plasma Triglycerides &gt; 10 g/L (&gt; 11.29 mmol/L) at Week 12</title>
          <description>Centralized laboratory assessment</description>
          <population>ITT. Missing values were excluded.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Cluster Determinant 4 (CD4) Cell Count</title>
        <description>Change = Week 12 value minus baseline value.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITT. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Cluster Determinant 4 (CD4) Cell Count</title>
          <description>Change = Week 12 value minus baseline value.</description>
          <population>ITT. Missing values were excluded.</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="-36.0" upper_limit="63.5"/>
                    <measurement group_id="O2" value="16.0" lower_limit="-31.0" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: changes from baseline in the two treatment groups are equal. Alternative Hypothesis: changes from baseline in the two treatment groups are different (two sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Wilcoxon Rank Sum test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in CD4 Cell Count</title>
        <description>Change = Week 48 value minus baseline value.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>ITT. Missing values were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in CD4 Cell Count</title>
          <description>Change = Week 48 value minus baseline value.</description>
          <population>ITT. Missing values were excluded.</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="-37.0" upper_limit="116.0"/>
                    <measurement group_id="O2" value="40.0" lower_limit="-41.5" upper_limit="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: no indication of shift from 0 in distribution of change from baseline. Alternative Hypothesis: shift from 0 is observed in distribution of change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <p_value_desc>No adjustments were made.</p_value_desc>
            <method>Wilcoxon Signed Rank test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: no indication of shift from 0 in distribution of change from baseline. Alternative Hypothesis: shift from 0 is observed in distribution of change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <p_value_desc>No adjustments were made.</p_value_desc>
            <method>Wilcoxon Signed Rank test</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Control (Plasma HIV-1 Ribonucleic Acid [RNA] &lt; 400 Copies/mL) at Week 12</title>
        <time_frame>12 weeks</time_frame>
        <population>ITT. Missing values were treated as failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Control (Plasma HIV-1 Ribonucleic Acid [RNA] &lt; 400 Copies/mL) at Week 12</title>
          <population>ITT. Missing values were treated as failure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: treatment is not associated with the observed virologic response. Alternative Hypothesis: treatment is associated with the observed virologic response</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>No adjustments were made.</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>No adjustments were made.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HIV-1 RNA Greater Than or Equal to 400 Copies/mL at Week 12</title>
        <time_frame>12 weeks</time_frame>
        <population>ITT. Missing values were excluded. Any subjects with plasma HIV-1 RNA greater than or equal to 400 copies/mL at Week 12 were to have virologic genotyping performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HIV-1 RNA Greater Than or Equal to 400 Copies/mL at Week 12</title>
          <population>ITT. Missing values were excluded. Any subjects with plasma HIV-1 RNA greater than or equal to 400 copies/mL at Week 12 were to have virologic genotyping performed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HIV-1 RNA &lt; 400 Copies/mL at Week 48</title>
        <time_frame>48 weeks</time_frame>
        <population>ITT. Missing values were treated as failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Truvada + NNRTI or PI.</description>
          </group>
          <group group_id="O2">
            <title>Maintain Baseline Regimen</title>
            <description>Maintain baseline regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HIV-1 RNA &lt; 400 Copies/mL at Week 48</title>
          <population>ITT. Missing values were treated as failure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Truvada</title>
          <description>Truvada + NNRTI or PI. The number of participants at risk is the number who started the study by switching to Truvada. Participants in this group were to remain on Truvada for 48 weeks (duration of the study). The number at risk was reduced only by study discontinuation (from 47 at baseline to 40 who completed Study Phase 2).</description>
        </group>
        <group group_id="E2">
          <title>Maintain Baseline Regimen</title>
          <description>Maintain baseline regimen. The number of participants at risk is the number who started the study by maintaining their baseline regimen. Per protocol, participants in this group were allowed to switch to Truvada after Week 12 (Delayed TVD group), therefore the number of participants at risk declines over time (from 45 at baseline to 17 who completed Study Phase 2; with most participants switching to Truvada at Week 12).</description>
        </group>
        <group group_id="E3">
          <title>All Truvada</title>
          <description>Truvada + NNRTI or PI (all participants who received Truvada during the study, i.e., participants in the Truvada and Delayed Truvada groups). The number of participants at risk is the number who started the study by switching to Truvada (Truvada group), plus those who started the study by maintaining their baseline regimen but who switched to Truvada during the study (Delayed Truvada group). The number of participants at risk increases over time (from 47 at baseline to 72 when the last switch to Truvada took place; 25 participants switched to Truvada from the &quot;maintain baseline regimen&quot; group in Study Phase 2).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead Sciences, investigators in this study may communicate, orally present, or publish in scientific journals or other scholarly media only after the following conditions have been met: results of the study in their entirety have been publicly disclosed by or with the consent of Gilead Sciences in an abstract, manuscript, or presentation form; or study has been completed at all study sites for at least 2 years.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Comparison of adverse events between Truvada and maintain baseline regimen groups is inappropriate since numbers at risk (and exposure to study drug) are not balanced, as described in the adverse event treatment group descriptions.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Camille Aubron-Olivier</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>+33(0)1 42 737130</phone>
      <email>camille.aubron-olivier@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

